LOGIN  |  REGISTER
Cue Biopharma
Amneal Pharmaceuticals

Varex Imaging to Hold Virtual Annual Meeting of Stockholders and Sets Annual Meeting and Record Dates

December 06, 2024 | Last Trade: US$12.33 0.00 0.00

SALT LAKE CITY / Dec 06, 2024 / Business Wire / Varex Imaging Corporation (Nasdaq: VREX) today announced that its 2025 Annual Meeting of Stockholders will be held in virtual format only at 4:30 pm Mountain Time on Thursday, February 13, 2025. Stockholders will not be able to attend the 2025 annual meeting in person.

Varex stockholders of record at the close of business on December 16, 2024 will be entitled to receive notice of the Annual Meeting and to vote upon matters considered at the meeting.

Varex will make available to all stockholders of record important information about the Annual Meeting and the matters to be considered. Information on how to attend the virtual meeting will be included in the meeting materials to be sent to stockholders. Varex urges stockholders to vote and submit their proxies in advance of the meeting by one of the methods described in the proxy materials.

About Varex

Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,300 people located in North America, Europe, and Asia. For more information visit vareximaging.com.

Assertio

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page